Study of the outcome of patients with lower urinary symptoms suggestive of benign prostatic hyperplasia and treated with alfuzosin 10 mg once daily for 3 months in China

Trial Profile

Study of the outcome of patients with lower urinary symptoms suggestive of benign prostatic hyperplasia and treated with alfuzosin 10 mg once daily for 3 months in China

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Alfuzosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ALF-ONE
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2006 Status change
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top